ArticleBlood advances2017

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

Daniel J DeAngelo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.